Stevenage, United Kingdom

Simon Christopher Cranko Lucas


 

Average Co-Inventor Count = 9.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2021-2022

Loading Chart...
Loading Chart...
3 patents (USPTO):Explore Patents

Title: Simon Christopher Cranko Lucas: Innovator in Pharmaceutical Chemistry

Introduction

Simon Christopher Cranko Lucas is a notable inventor based in Stevenage, GB. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of compounds that serve as bromodomain inhibitors. With a total of three patents to his name, Lucas is recognized for his innovative approach to drug development.

Latest Patents

Among his latest patents, Lucas has developed two key inventions. The first patent is for "2,3-dihydrobenzohurans as bromodomain inhibitors." This invention relates to compounds of formula (I) and their salts, along with pharmaceutical compositions containing such compounds and their therapeutic uses. The second patent focuses on "Benzofuran derivatives and their use as bromodomain inhibitors." Similar to the first, this invention also pertains to compounds of formula (I) and their salts, emphasizing their application in therapy.

Career Highlights

Lucas is currently associated with GlaxoSmithKline Intellectual Property (No. 2) Limited, where he continues to advance his research and development efforts. His work has been instrumental in creating innovative solutions that address critical health challenges.

Collaborations

Throughout his career, Lucas has collaborated with esteemed colleagues, including Stephen John Atkinson and Emmanuel Hubert Demont. These partnerships have fostered a collaborative environment that enhances the potential for groundbreaking discoveries.

Conclusion

In summary, Simon Christopher Cranko Lucas is a distinguished inventor whose work in pharmaceutical chemistry has led to significant advancements in drug development. His contributions, particularly in the area of bromodomain inhibitors, highlight his commitment to improving therapeutic options.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…